文献速递眼底病与葡萄膜炎

美国湿性年龄相关性黄斑变性患者抗血管内皮生长因子治疗的经济价值

Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该经济评估研究基于已发表文献模拟168820例65岁及以上湿性年龄相关性黄斑变性患者的视力结局并转化为经济变量。改善依从性和最佳情形下3年收益更高,提示抗VEGF治疗相关视力改善可能为患者和社会提供经济价值。

要点

  • 基于168820例65岁以上湿性年龄相关性黄斑变性患者模拟,评估抗VEGF治疗的经济价值。

核心结论

  • 与抗VEGF治疗相关的视力改善可能为患者和社会提供经济价值,前提是结局与本文分析所用的已发表结局数据一致;未来提高治疗利用率的创新可能带来额外经济收益。

研究设计与样本

  • 经济评估研究,使用已发表文献数据模拟168820例65岁及以上湿性年龄相关性黄斑变性患者的视力结局并转化为经济变量,数据收集与分析时间为2018年3月至2018年11月。
  • 主要结局包括患者获益、成本和社会价值,分别对新诊断队列和全人群估算5年内的结局,以第3年作为主要结局。
  • 药物成本取各抗VEGF治疗的加权均值;考虑两种当前治疗情景:较低频注射(年均8.2次,标准差1.6)和较高频注射(年均10.5次,范围6.8至13.1次)。
  • 两种治疗创新情景(改善依从性和最佳情形)的视力结局与当前治疗情景相同,但纳入更多治疗患者,源于更高的起始治疗率和更低的终止治疗率。

局限性

  • 用于参数化模型的原始临床试验未按性别分层报告视力结局或治疗频率,因此模型参数无法按性别分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-vascular endothelial growth factor (anti-VEGF) is a breakthrough treatment for wet age-related macular degeneration (wAMD), the most common cause of blindness in western countries. Anti-VEGF treatment prevents vision loss and has been shown to produce vision gains lasting as long as 5 years. Although this treatment is costly, the benefits associated with vision gains are large. OBJECTIVE: To estimate the economic value of benefits, costs for patients with wAMD, and societal value in the United States generated from vision improvement associated with anti-VEGF treatment. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study used data from the published literature to simulate vision outcomes for a cohort of 168 820 patients with wAMD aged 65 years or older and to translate them into economic variables. Data were collected and analyzed from March 2018 to November 2018. MAIN OUTCOMES AND MEASURES: Main outcomes included patient benefits, costs, and societal value. Each outcome was estimated for a newly diagnosed cohort and the full population across 5 years, with a focus on year 3 as the primary outcome because data beyond that point may be less representative of the general population. Drug costs were the weighted mean across anti-VEGF therapies. Two current treatment scenarios were considered: less frequent injections (mean [SD], 8.2 [1.6] injections annually) and more frequent injections (mean [range], 10.5 [6.8-13.1] injections annually). The 2 treatment innovation scenarios, improved adherence and best case, had the same vision outcomes as the current treatment scenarios had but included more patients treated from higher initiation and lower discontinuation. RESULTS: The study population included 168 820 patients aged 65 years at the time of diagnosis with wAMD. The underlying clinical trials that were used to parameterize the model did not stratify visual acuity outcomes or treatment frequency by sex; therefore, the model parameters could not be stratified by sex. The current treatment scenario of less frequent injections generated $1.1 billion for the full population in year 1 and $5.1 billion in year 3, whereas the scenario of more frequent injections generated $1.6 billion (year 1) and $8.2 billion (year 3). Three-year benefits ranged from $7.3 billion to $11.4 billion in the improved adherence scenario and from $9.7 billion to $15.0 billion if 100% of the patients initiated anti-VEGF treatment and the discontinuation rates were 6% per year or equivalent to clinical trial discontinuation (best-case scenario). Societal value (patient benefits net of treatment cost) ranged from $0.9 billion to $3.0 billion across 3 years in the current treatment scenarios and from $0.9 billion to $4.3 billion in the treatment innovation scenarios. CONCLUSIONS AND RELEVANCE: This study's findings suggest that improved vision associated with anti-VEGF treatment may provide economic value to patients and society if the outcomes match published outcomes data used in these analyses; however, future innovations that increase treatment utilization may result in added economic benefit.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mulligan K, Seabury SA, Dugel PU, et al. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States. JAMA Ophthalmol. 2020. PMID: 31725830. doi:10.1001/jamaophthalmol.2019.4557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。